Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.69 |
| ▸ | F2 | P00734 | 11/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 8/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 8/20 | 0.67 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | F9 | P00740 | 1/20 | 0.51 |
| ▸ | PROC | P04070 | 1/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6602814 | 0.93 | F10 (0.69) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6605384 | 0.87 | F10 (0.69) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6604182 | 0.86 | F10 (0.70) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6604002 | 0.84 | F10 (0.70) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6603523 | 0.82 | F10 (1.00) | F10F2F9PROC | |
| SCHEMBL6604647 | 0.81 | F10 (0.70) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6605343 | 0.81 | F10 (0.70) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6602824 | 0.80 | F10 (0.69) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6603360 | 0.78 | F10 (1.00) | F10F2F9PROC | |
| SCHEMBL6603165 | 0.77 | F10 (0.71) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196412-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-06-09 | — | — | EP | claimed |
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2003-05-22 | — | — | US | claimed |
| US-6429205-B1 | ANTICOAGULANTS | BRISTOL-MEYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | claimed |
| EP-1196412-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6716841-B2 | SUCH AS 1-((1-(3-(AMINOMETHYL)PHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-5-YL)CARBONYL) -5-(2-( AMINOSULFONYL)PHENYL)-2,3-DIHYDRO-1H-INDOLE FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2003-05-22 | — | — | US | disclosed |
| US-6429205-B1 | ANTICOAGULANTS | BRISTOL-MEYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | SERPINC1, CTRB1, F2 | F10 25/4885F2 3/4885PRSS1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.